Hims & Hers Health (HIMS) Financials

$61.21 -1.13 (-1.81%)

As of 05/20/2025 03:58 PM Eastern

Annual Income Statements for Hims & Hers Health

This table shows Hims & Hers Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Net Income / (Loss) Attributable to Common Shareholders	126	-24	-66	-108	-18	-72
Consolidated Net Income / (Loss)	126	-24	-66	-108	-18	-72
Net Income / (Loss) Continuing Operations	126	-24	-66	-108	-18	-72
Total Pre-Tax Income	72	-22	-66	-111	-18	-72
Total Operating Income	62	-29	-69	-115	-15	-74
Total Gross Profit	1,173	715	409	204	109	45
Total Revenue	1,477	872	527	272	149	83
Operating Revenue	1,477	872	527	272	149	83
Total Cost of Revenue	303	157	118	67	39	38
Operating Cost of Revenue	303	157	118	67	39	38
Total Operating Expenses	1,111	744	477	320	125	119
Selling, General & Admin Expense	168	130	98	114	26	56
Marketing Expense	679	446	273	136	59	63
Research & Development Expense	79	48	29	22	11	-
Other Operating Expenses / (Income)	186	120	77	48	28	-
Total Other Income / (Expense), net	9.81	7.88	2.99	4.25	-2.84	2.44
Other Income / (Expense), net	9.81	7.88	2.99	4.25	-2.84	2.81
Income Tax Expense	-54	1.98	-0.03	-3.14	0.13	0.09
Basic Earnings per Share	$0.58	($0.11)	($0.32)	($0.58)	($0.51)	($2.07)
Weighted Average Basic Shares Outstanding	215.94M	209.34M	204.52M	186.78M	35.35M	34.76M
Diluted Earnings per Share	$0.53	($0.11)	($0.32)	($0.58)	($0.51)	($2.07)
Weighted Average Diluted Shares Outstanding	236.81M	209.34M	204.52M	186.78M	35.35M	34.76M
Weighted Average Basic & Diluted Shares Outstanding	222.17M	214.25M	208.46M	205.07M	5.03M	-

This table shows Hims & Hers Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	49	26	76	13	11	1.25	-7.57	-7.16	-10	-11	-19
Consolidated Net Income / (Loss)	49	26	76	13	11	1.25	-7.57	-7.16	-10	-11	-19
Net Income / (Loss) Continuing Operations	49	26	76	13	11	1.25	-7.57	-7.16	-10	-11	-19
Total Pre-Tax Income	60	22	24	13	12	2.20	-6.92	-7.17	-9.68	-11	-19
Total Operating Income	58	19	22	11	9.90	-0.40	-8.55	-9.24	-11	-12	-20
Total Gross Profit	431	370	318	257	229	204	187	170	153	132	114
Total Revenue	586	481	402	316	278	247	227	208	191	167	145
Operating Revenue	586	481	402	316	278	247	227	208	191	167	145
Total Cost of Revenue	155	112	84	59	49	43	39	38	37	35	30
Operating Cost of Revenue	155	112	84	59	49	43	39	38	37	35	30
Total Operating Expenses	373	351	296	246	219	204	196	179	165	144	134
Selling, General & Admin Expense	49	48	45	41	35	32	36	31	31	28	26
Marketing Expense	231	221	182	145	131	126	116	107	97	86	78
Research & Development Expense	30	24	21	19	15	13	12	12	11	8.31	7.98
Other Operating Expenses / (Income)	63	58	48	41	39	33	32	29	26	23	22
Total Other Income / (Expense), net	2.60	3.70	1.22	2.39	2.50	2.60	1.64	2.07	1.58	0.58	1.13
Other Income / (Expense), net	2.60	3.70	1.22	2.39	2.50	2.60	1.64	2.07	1.58	0.58	1.13
Income Tax Expense	11	-3.73	-52	0.13	1.28	0.95	0.65	-0.01	0.39	-0.12	-0.02
Basic Earnings per Share	$0.22	$0.12	$0.35	$0.06	$0.05	$0.01	($0.04)	($0.03)	($0.05)	($0.05)	($0.09)
Weighted Average Basic Shares Outstanding	221.99M	215.94M	216.62M	214.62M	213.45M	209.34M	210.13M	208.42M	207.14M	204.52M	205.23M
Diluted Earnings per Share	$0.20	$0.10	$0.32	$0.06	$0.05	$0.01	($0.04)	($0.03)	($0.05)	($0.05)	($0.09)
Weighted Average Diluted Shares Outstanding	246.61M	236.81M	235.07M	234.79M	229.36M	209.34M	210.13M	208.42M	207.14M	204.52M	205.23M
Weighted Average Basic & Diluted Shares Outstanding	223.83M	222.17M	218.48M	217.08M	214.79M	214.25M	211.99M	211.02M	209.32M	208.46M	207.74M

This table details how cash moves in and out of Hims & Hers Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Net Change in Cash & Equivalents	124	50	-25	44	5.55	-19
Net Cash From Operating Activities	251	73	-27	-34	-2.48	-75
Net Cash From Continuing Operating Activities	251	73	-27	-34	-2.48	-75
Net Income / (Loss) Continuing Operations	126	-24	-66	-108	-18	-72
Consolidated Net Income / (Loss)	126	-24	-66	-108	-18	-72
Depreciation Expense	17	9.52	7.47	4.08	1.06	0.26
Amortization Expense	-4.36	-5.69	0.15	2.31	0.65	-0.13
Non-Cash Adjustments To Reconcile Net Income	93	72	36	67	9.75	6.92
Changes in Operating Assets and Liabilities, net	20	21	-4.61	0.07	4.19	-9.85
Net Cash From Investing Activities	-19	-12	35	-156	-40	-39
Net Cash From Continuing Investing Activities	-19	-12	35	-156	-40	-39
Purchase of Property, Plant & Equipment	-53	-26	-7.25	-5.01	-4.23	-1.79
Acquisitions	-15	0.00	-0.46	-46	0.00	0.00
Purchase of Investments	-161	-157	-188	-267	-95	-42
Sale and/or Maturity of Investments	210	172	230	162	60	4.50
Net Cash From Financing Activities	-108	-11	-33	235	48	95
Net Cash From Continuing Financing Activities	-108	-11	-33	235	48	95
Repurchase of Common Equity	-83	-2.00	0.00	-35	-3.36	0.00
Issuance of Common Equity	3.90	2.30	1.18	75	0.00	0.00
Other Financing Activities, net	-29	-12	-34	194	0.68	0.04
Effect of Exchange Rate Changes	-0.27	-0.01	-0.05	-0.07	-0.01	-0.01
Cash Income Taxes Paid	7.92	1.11	0.64	0.34	0.22	0.14

This table details how cash moves in and out of Hims & Hers Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	54	55	36	24	8.57	39	-7.42	17	1.97	-11	2.93
Net Cash From Operating Activities	109	86	85	54	26	22	25	17	9.48	-6.72	5.99
Net Cash From Continuing Operating Activities	109	86	85	54	26	22	25	17	9.48	-6.72	5.99
Net Income / (Loss) Continuing Operations	49	26	76	13	11	1.25	-7.57	-7.16	-10	-11	-19
Consolidated Net Income / (Loss)	49	26	76	13	11	1.25	-7.57	-7.16	-10	-11	-19
Depreciation Expense	8.28	6.06	4.38	3.64	3.00	2.66	2.36	2.38	2.12	2.01	1.90
Amortization Expense	-0.69	-0.92	-1.16	-1.20	-1.08	-1.65	-1.52	-1.48	-1.04	-0.84	0.12
Non-Cash Adjustments To Reconcile Net Income	29	25	26	22	20	19	20	18	16	11	12
Changes in Operating Assets and Liabilities, net	23	30	-19	16	-7.30	0.88	12	5.17	2.45	-8.42	11
Net Cash From Investing Activities	-33	-17	-10	-4.47	13	21	-31	2.37	-4.11	6.00	-2.58
Net Cash From Continuing Investing Activities	-33	-17	-10	-4.47	13	21	-31	2.37	-4.11	6.00	-2.58
Purchase of Property, Plant & Equipment	-59	-27	-5.88	-6.03	-14	-11	-5.92	-6.86	-2.51	-2.61	-1.96
Acquisitions	-5.10	-	-	-	-	-	-	-	-	-	-
Purchase of Investments	0.00	-9.97	-53	-27	-71	-21	-71	-25	-41	-51	-48
Sale and/or Maturity of Investments	31	20	64	28	98	53	46	34	39	60	47
Net Cash From Financing Activities	-23	-14	-39	-25	-30	-3.96	-1.56	-2.54	-3.41	-10	-0.49
Net Cash From Continuing Financing Activities	-23	-14	-39	-25	-30	-3.96	-1.56	-2.54	-3.41	-10	-0.49
Repayment of Debt	-1.24	-	-	-	-	-	-	-	-	-	-
Repurchase of Common Equity	0.00	-5.01	-30	-20	-28	-2.00	-	-	0.00	-	-
Other Financing Activities, net	-22	-11	-8.78	-6.76	-2.24	-3.36	-1.56	-3.44	-3.41	-11	-0.49
Effect of Exchange Rate Changes	0.24	-0.46	0.19	-0.00	0.00	-0.05	0.01	0.01	0.02	-0.02	0.02
Cash Income Taxes Paid	0.36	4.04	0.40	3.34	0.13	0.46	0.02	0.34	0.29	0.05	0.06

This table presents Hims & Hers Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Total Assets	708	441	366	421	119	205
Total Current Assets	396	265	217	270	113	1.66
Cash & Equivalents	221	97	47	72	27	1.51
Short-Term Investments	80	124	133	175	73	-
Inventories, net	64	22	22	14	3.54	-
Prepaid Expenses	31	22	15	9.07	5.40	0.15
Plant, Property, & Equipment, net	0.00	0.00	0.00	0.00	0.00	0.00
Total Noncurrent Assets	312	176	150	151	5.61	203
Goodwill	113	111	111	111	0.00	-
Intangible Assets	43	19	22	26	0.06	-
Noncurrent Deferred & Refundable Income Taxes	62	0.00	-	-	-	-
Other Noncurrent Operating Assets	94	47	17	14	5.55	203
Total Liabilities & Shareholders' Equity	708	441	366	421	119	205
Total Liabilities	231	97	55	86	16	8.17
Total Current Liabilities	221	88	48	79	15	0.98
Short-Term Debt	0.00	7.41	0.00	43	0.00	-
Accounts Payable	91	43	32	20	8.07	0.45
Accrued Expenses	53	29	12	12	4.98	0.53
Current Deferred Revenue	75	7.73	1.47	3.19	1.27	-
Other Current Liabilities	1.89	1.28	1.66	1.37	0.91	-
Total Noncurrent Liabilities	9.46	8.69	6.66	6.75	0.38	7.19
Other Noncurrent Operating Liabilities	9.46	8.69	6.66	6.75	0.38	7.19
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	477	344	312	335	-147	5.00
Total Preferred & Common Equity	477	344	312	335	-147	5.00
Total Common Equity	477	344	312	335	-147	5.00
Common Stock	719	712	657	614	24	3.85
Retained Earnings	-242	-368	-345	-279	-171	1.15
Accumulated Other Comprehensive Income / (Loss)	-0.32	-0.12	-0.28	-0.14	-0.01	-

This table presents Hims & Hers Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	892	602	481	448	414	390	376	383
Total Current Assets	447	326	291	262	250	235	226	233
Cash & Equivalents	274	166	129	105	58	65	49	58
Short-Term Investments	49	89	98	98	155	128	136	140
Inventories, net	76	49	41	30	22	21	21	22
Prepaid Expenses	48	23	23	28	16	20	20	13
Plant, Property, & Equipment, net	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Noncurrent Assets	445	276	190	186	164	155	151	149
Goodwill	118	113	111	111	111	111	111	111
Intangible Assets	43	45	17	18	19	20	21	22
Noncurrent Deferred & Refundable Income Taxes	62	54	-	-	-	-	-	-
Other Noncurrent Operating Assets	221	64	62	58	33	24	19	16
Total Liabilities & Shareholders' Equity	892	602	481	448	414	390	376	383
Total Liabilities	342	162	119	104	85	70	64	72
Total Current Liabilities	280	153	109	93	83	67	56	67
Accounts Payable	109	75	57	44	42	38	38	33
Accrued Expenses	57	43	29	27	27	20	14	17
Current Deferred Revenue	111	32	21	14	4.39	2.06	2.87	2.12
Other Current Liabilities	3.74	1.79	1.63	1.54	1.93	1.84	1.69	1.61
Total Noncurrent Liabilities	62	9.57	9.86	10	2.76	3.27	7.28	5.06
Other Noncurrent Operating Liabilities	62	9.57	9.86	10	2.76	3.27	7.28	5.06
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	549	440	362	344	329	320	313	311
Total Preferred & Common Equity	549	440	362	344	329	320	313	311
Total Common Equity	549	440	362	344	329	320	313	311
Common Stock	742	708	706	702	698	682	668	645
Retained Earnings	-193	-268	-344	-357	-369	-362	-355	-334
Accumulated Other Comprehensive Income / (Loss)	-0.16	0.23	-0.17	-0.16	-0.13	-0.26	-0.11	-0.46

This table displays calculated financial ratios and metrics derived from Hims & Hers Health's official financial filings.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Growth Metrics	-	-	-	-	-	-
Revenue Growth	69.33%	65.49%	93.81%	82.77%	80.18%	0.00%
EBITDA Growth	575.96%	69.46%	44.36%	-541.22%	77.22%	0.00%
EBIT Growth	432.44%	67.17%	40.69%	-515.97%	74.88%	0.00%
NOPAT Growth	627.72%	57.13%	40.29%	-659.65%	79.65%	0.00%
Net Income Growth	635.28%	64.15%	38.99%	-494.34%	74.86%	0.00%
EPS Growth	581.82%	65.63%	44.83%	-13.73%	75.36%	0.00%
Operating Cash Flow Growth	241.69%	376.97%	22.90%	-1,288.14%	96.69%	0.00%
Free Cash Flow Firm Growth	431.18%	62.10%	75.93%	-214.44%	0.00%	0.00%
Invested Capital Growth	35.26%	-1.25%	1.49%	4,420.10%	-98.52%	0.00%
Revenue Q/Q Growth	18.88%	10.02%	18.56%	18.91%	0.00%	0.00%
EBITDA Q/Q Growth	40.25%	42.53%	24.96%	-31.04%	0.00%	0.00%
EBIT Q/Q Growth	38.93%	38.13%	23.53%	-30.71%	0.00%	0.00%
NOPAT Q/Q Growth	29.26%	27.56%	12.66%	-17.27%	0.00%	0.00%
Net Income Q/Q Growth	24.47%	34.04%	23.57%	-31.73%	0.00%	0.00%
EPS Q/Q Growth	20.45%	35.29%	15.79%	6.45%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	34.50%	64.09%	-15.77%	-8.98%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	197.32%	26.68%	8.47%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	-5.12%	6.13%	5.25%	3.37%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	79.45%	81.99%	77.57%	75.22%	73.58%	54.03%
EBITDA Margin	5.72%	-2.03%	-11.02%	-38.40%	-10.95%	-86.58%
Operating Margin	4.19%	-3.38%	-13.04%	-42.31%	-10.18%	-90.14%
EBIT Margin	4.86%	-2.47%	-12.47%	-40.75%	-12.09%	-86.73%
Profit (Net Income) Margin	8.54%	-2.70%	-12.46%	-39.60%	-12.18%	-87.29%
Tax Burden Percent	175.76%	109.16%	99.95%	97.17%	100.71%	100.13%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.52%
Effective Tax Rate	-75.76%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	70.90%	-15.70%	-36.67%	-121.04%	-10.71%	-26.70%
ROIC Less NNEP Spread (ROIC-NNEP)	64.19%	-14.21%	-27.51%	-103.23%	4.06%	1,295.79%
Return on Net Nonoperating Assets (RNNOA)	-40.18%	8.52%	16.34%	71.85%	-1.38%	-9.96%
Return on Equity (ROE)	30.71%	-7.18%	-20.32%	-49.19%	-12.09%	-36.66%
Cash Return on Invested Capital (CROIC)	40.92%	-14.44%	-38.14%	-312.39%	183.47%	0.00%
Operating Return on Assets (OROA)	12.49%	-5.34%	-16.70%	-41.09%	-11.12%	-34.97%
Return on Assets (ROA)	21.94%	-5.83%	-16.69%	-39.93%	-11.20%	-35.19%
Return on Common Equity (ROCE)	30.71%	-7.18%	-20.32%	-21.10%	5.72%	-0.93%
Return on Equity Simple (ROE_SIMPLE)	26.44%	-6.84%	-21.07%	-32.17%	12.33%	-1,441.28%
Net Operating Profit after Tax (NOPAT)	109	-21	-48	-81	-11	-52
NOPAT Margin	7.37%	-2.36%	-9.13%	-29.62%	-7.13%	-63.09%
Net Nonoperating Expense Percent (NNEP)	6.71%	-1.49%	-9.16%	-17.81%	-14.77%	-1,322.50%
Return On Investment Capital (ROIC_SIMPLE)	22.82%	-5.87%	-15.43%	-	-	-
Cost of Revenue to Revenue	20.55%	18.01%	22.43%	24.78%	26.42%	45.97%
SG&A Expenses to Revenue	11.36%	14.89%	18.64%	41.81%	17.50%	67.67%
R&D to Revenue	5.34%	5.53%	5.55%	8.23%	7.55%	0.00%
Operating Expenses to Revenue	75.26%	85.37%	90.61%	117.53%	83.76%	144.16%
Earnings before Interest and Taxes (EBIT)	72	-22	-66	-111	-18	-72
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	84	-18	-58	-104	-16	-71
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	11.08	5.48	4.27	3.99	0.00	49.81
Price to Tangible Book Value (P/TBV)	16.48	8.79	7.44	6.75	0.00	49.81
Price to Revenue (P/Rev)	3.58	2.16	2.53	4.91	2.47	3.02
Price to Earnings (P/E)	41.91	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	2.39%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	28.24	12.83	8.72	8.69	179.53	2.25
Enterprise Value to Revenue (EV/Rev)	3.37	1.92	2.19	4.16	3.48	5.32
Enterprise Value to EBITDA (EV/EBITDA)	59.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	69.48	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	45.80	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	19.84	22.77	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	79.35	0.00	0.00	0.00	2.85	0.00
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.00	0.02	0.00	0.13	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.63	-0.60	-0.59	-0.70	-0.34	-0.01
Leverage Ratio	1.40	1.23	1.22	1.23	1.08	1.04
Compound Leverage Factor	1.40	1.23	1.22	1.23	1.08	1.05
Debt to Total Capital	0.00%	2.11%	0.00%	11.35%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	2.11%	0.00%	11.35%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	242.47%	97.46%
Common Equity to Total Capital	100.00%	97.89%	100.00%	88.65%	-142.47%	2.54%
Debt to EBITDA	0.00	-0.42	0.00	-0.41	0.00	0.00
Net Debt to EBITDA	0.00	12.04	0.00	1.96	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	-0.36	0.00	-0.53	0.00	0.00
Net Debt to NOPAT	0.00	10.36	0.00	2.54	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	15.97	12.78	14.71	8.71	13.84	17.54
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	57.11%	147.34%	97.46%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	1.79	3.00	4.52	3.41	7.43	1.69
Quick Ratio	1.36	2.50	3.75	3.12	6.58	1.54
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	63	-19	-50	-208	182	0.00
Operating Cash Flow to CapEx	475.99%	277.38%	-366.10%	-687.28%	-58.56%	-4,189.54%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	-202.89
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	-207.73
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	2.57	2.16	1.34	1.01	0.92	0.40
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	6.98	7.13	6.73	7.88	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	4.52	4.16	4.55	4.86	9.24	85.10
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	52.27	51.16	54.23	46.32	0.00	0.00
Days Payable Outstanding (DPO)	80.76	87.66	80.30	75.04	39.52	4.29
Cash Conversion Cycle (CCC)	-28.49	-36.50	-26.07	-28.72	-39.52	-4.29
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	176	130	132	130	2.88	195
Invested Capital Turnover	9.62	6.64	4.02	4.09	1.50	0.42
Increase / (Decrease) in Invested Capital	46	-1.66	1.94	127	-192	0.00
Enterprise Value (EV)	4,983	1,673	1,152	1,131	517	439
Market Capitalization	5,283	1,887	1,332	1,336	367	249
Book Value per Share	$2.18	$1.62	$1.50	$1.64	($5.84)	$0.20
Tangible Book Value per Share	$1.47	$1.01	$0.86	$0.97	($5.84)	$0.20
Total Capital	477	351	312	377	103	197
Total Debt	0.00	7.41	0.00	43	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-300	-214	-180	-204	-100	-1.51
Capital Expenditures (CapEx)	53	26	7.25	5.01	4.23	1.79
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-126	-37	-11	-14	-2.35	-0.83
Debt-free Net Working Capital (DFNWC)	174	184	169	234	98	0.68
Net Working Capital (NWC)	174	177	169	191	98	0.68
Net Nonoperating Expense (NNE)	-17	2.93	18	27	7.51	20
Net Nonoperating Obligations (NNO)	-300	-214	-180	-204	-100	-1.51
Total Depreciation and Amortization (D&A)	13	3.83	7.62	6.39	1.70	0.13
Debt-free, Cash-free Net Working Capital to Revenue	-8.52%	-4.24%	-2.08%	-5.06%	-1.58%	-1.01%
Debt-free Net Working Capital to Revenue	11.82%	21.10%	32.01%	85.89%	65.78%	0.82%
Net Working Capital to Revenue	11.82%	20.25%	32.01%	70.14%	65.78%	0.82%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.58	($0.11)	($0.32)	($0.58)	($0.96)	$0.00
Adjusted Weighted Average Basic Shares Outstanding	215.94M	209.34M	204.52M	186.78M	191.35M	0.00
Adjusted Diluted Earnings per Share	$0.53	($0.11)	($0.32)	($0.58)	($0.96)	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	236.81M	209.34M	204.52M	186.78M	191.35M	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	($0.96)	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	222.17M	214.25M	208.46M	205.07M	25.16M	0.00
Normalized Net Operating Profit after Tax (NOPAT)	43	-21	-48	-81	-11	-52
Normalized NOPAT Margin	2.93%	-2.36%	-9.13%	-29.62%	-7.13%	-63.09%
Pre Tax Income Margin	4.86%	-2.47%	-12.47%	-40.75%	-12.09%	-87.18%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	-194.05
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	-141.16
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	-198.89
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	-146.01
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	65.88%	-8.49%	0.00%	-32.40%	-18.53%	0.00%

This table displays calculated financial ratios and metrics derived from Hims & Hers Health's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	110.67%	95.09%	77.13%	51.82%	45.81%	47.50%	56.52%	83.08%	88.30%	97.41%	95.27%
EBITDA Growth	375.17%	756.87%	541.80%	353.04%	266.50%	132.48%	63.94%	65.08%	36.00%	66.22%	-2.65%
EBIT Growth	387.74%	915.07%	441.14%	287.22%	228.12%	119.91%	63.32%	63.54%	40.09%	64.71%	1.35%
NOPAT Growth	433.03%	9,673.78%	1,297.14%	268.99%	212.70%	97.21%	57.19%	54.25%	33.43%	46.19%	27.76%
Net Income Growth	344.69%	1,990.36%	1,098.92%	285.79%	210.54%	111.41%	59.84%	63.63%	38.06%	65.00%	-18.19%
EPS Growth	300.00%	900.00%	900.00%	300.00%	200.00%	120.00%	55.56%	70.00%	37.50%	54.55%	-12.50%
Operating Cash Flow Growth	322.21%	292.96%	238.48%	218.52%	172.47%	427.18%	320.90%	363.15%	148.87%	-116.39%	137.50%
Free Cash Flow Firm Growth	-179.51%	-1,799.80%	354.72%	812.83%	-891.54%	114.21%	75.06%	99.36%	100.78%	92.93%	-127.70%
Invested Capital Growth	52.79%	35.26%	51.29%	2.25%	15.54%	-1.25%	-2.07%	-3.90%	-6.74%	1.49%	-0.32%
Revenue Q/Q Growth	21.80%	19.82%	27.22%	13.47%	12.79%	8.79%	9.04%	8.99%	14.09%	15.44%	27.54%
EBITDA Q/Q Growth	148.12%	2.31%	69.05%	10.72%	347.44%	152.75%	3.17%	27.15%	13.33%	41.43%	6.25%
EBIT Q/Q Growth	171.39%	-5.52%	75.75%	8.23%	464.80%	131.75%	3.54%	25.94%	12.77%	41.51%	4.12%
NOPAT Q/Q Growth	118.14%	-69.71%	556.09%	22.97%	4,017.96%	96.21%	7.38%	18.00%	2.95%	41.93%	1.03%
Net Income Q/Q Growth	90.14%	-65.57%	468.46%	19.49%	793.82%	116.45%	-5.73%	28.91%	7.70%	42.11%	4.26%
EPS Q/Q Growth	100.00%	-68.75%	433.33%	20.00%	400.00%	125.00%	-33.33%	40.00%	0.00%	44.44%	10.00%
Operating Cash Flow Q/Q Growth	26.28%	1.31%	59.10%	107.42%	17.54%	-12.73%	49.71%	77.43%	241.14%	-212.26%	193.60%
Free Cash Flow Firm Q/Q Growth	-27.31%	-381.52%	8.46%	171.91%	-874.20%	142.19%	-203.51%	-179.85%	113.89%	25.93%	92.26%
Invested Capital Q/Q Growth	28.41%	-5.12%	38.10%	-9.19%	13.68%	6.13%	-6.66%	2.61%	-2.85%	5.25%	-8.41%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	73.50%	76.81%	79.16%	81.30%	82.36%	82.74%	82.62%	81.84%	80.42%	79.15%	79.02%
EBITDA Margin	11.62%	5.70%	6.68%	5.03%	5.15%	1.30%	-2.68%	-3.02%	-4.51%	-5.90%	-11.62%
Operating Margin	9.88%	3.87%	5.57%	3.49%	3.56%	-0.16%	-3.77%	-4.44%	-5.90%	-6.94%	-13.80%
EBIT Margin	10.32%	4.63%	5.88%	4.25%	4.46%	0.89%	-3.05%	-3.45%	-5.07%	-6.60%	-13.02%
Profit (Net Income) Margin	8.44%	5.41%	18.82%	4.21%	4.00%	0.50%	-3.34%	-3.44%	-5.28%	-6.52%	-13.01%
Tax Burden Percent	81.80%	116.75%	320.38%	99.05%	89.72%	56.69%	109.41%	99.82%	103.99%	98.90%	99.92%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	18.20%	-16.75%	-220.38%	0.95%	10.28%	43.31%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	76.93%	43.42%	143.55%	27.73%	22.15%	-0.61%	-16.85%	-16.45%	-19.15%	-19.52%	-34.14%
ROIC Less NNEP Spread (ROIC-NNEP)	76.11%	41.74%	141.85%	26.59%	20.97%	-1.36%	-16.04%	-16.07%	-17.99%	-18.07%	-31.80%
Return on Net Nonoperating Assets (RNNOA)	-44.19%	-26.13%	-84.84%	-16.21%	-12.15%	0.82%	9.81%	9.31%	10.52%	10.74%	19.79%
Return on Equity (ROE)	32.75%	17.29%	58.71%	11.53%	10.01%	0.20%	-7.04%	-7.13%	-8.64%	-8.78%	-14.34%
Cash Return on Invested Capital (CROIC)	38.69%	40.92%	13.67%	5.48%	13.03%	-14.44%	-20.82%	-23.15%	-26.20%	-38.14%	-43.47%
Operating Return on Assets (OROA)	27.50%	11.91%	14.36%	10.43%	10.38%	1.92%	-6.07%	-6.37%	-8.25%	-8.83%	-14.41%
Return on Assets (ROA)	22.49%	13.91%	46.02%	10.33%	9.31%	1.09%	-6.64%	-6.36%	-8.58%	-8.74%	-14.40%
Return on Common Equity (ROCE)	32.75%	17.29%	58.71%	11.53%	10.01%	0.20%	-7.04%	-7.13%	-8.64%	-8.78%	-14.34%
Return on Equity Simple (ROE_SIMPLE)	29.93%	0.00%	23.01%	5.00%	-0.68%	0.00%	-10.86%	-14.68%	-19.02%	0.00%	-27.64%
Net Operating Profit after Tax (NOPAT)	47	22	72	11	8.88	-0.23	-5.99	-6.47	-7.88	-8.12	-14
NOPAT Margin	8.08%	4.51%	17.85%	3.46%	3.19%	-0.09%	-2.64%	-3.11%	-4.13%	-4.86%	-9.66%
Net Nonoperating Expense Percent (NNEP)	0.82%	1.68%	1.70%	1.14%	1.18%	0.75%	-0.81%	-0.37%	-1.17%	-1.45%	-2.34%
Return On Investment Capital (ROIC_SIMPLE)	8.62%	4.55%	-	-	-	-0.06%	-	-	-	-2.61%	-
Cost of Revenue to Revenue	26.50%	23.19%	20.84%	18.70%	17.64%	17.26%	17.38%	18.16%	19.58%	20.85%	20.98%
SG&A Expenses to Revenue	8.30%	9.98%	11.11%	12.85%	12.43%	13.10%	15.84%	14.98%	15.99%	16.49%	18.12%
R&D to Revenue	5.10%	4.94%	5.25%	5.91%	5.51%	5.44%	5.41%	5.68%	5.63%	4.97%	5.51%
Operating Expenses to Revenue	63.62%	72.94%	73.59%	77.80%	78.80%	82.90%	86.40%	86.28%	86.33%	86.09%	92.82%
Earnings before Interest and Taxes (EBIT)	60	22	24	13	12	2.20	-6.92	-7.17	-9.68	-11	-19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	68	27	27	16	14	3.20	-6.07	-6.27	-8.61	-9.86	-17
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	11.95	11.08	9.09	11.98	9.52	5.48	4.04	6.15	6.61	4.27	3.72
Price to Tangible Book Value (P/TBV)	16.92	16.48	14.15	18.54	15.20	8.79	6.69	10.40	11.43	7.44	6.49
Price to Revenue (P/Rev)	3.68	3.58	3.22	4.06	3.42	2.16	1.67	2.77	3.36	2.53	2.60
Price to Earnings (P/E)	39.93	41.91	39.51	240.13	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	2.50%	2.39%	2.53%	0.42%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	27.55	28.24	20.13	30.51	20.79	12.83	9.12	13.51	14.67	8.72	7.73
Enterprise Value to Revenue (EV/Rev)	3.50	3.37	3.01	3.85	3.21	1.92	1.42	2.50	3.06	2.19	2.18
Enterprise Value to EBITDA (EV/EBITDA)	45.17	59.00	62.19	150.40	594.10	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	52.10	69.48	72.55	194.69	6,010.45	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	41.39	45.80	44.49	399.96	81.19	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	18.67	19.84	20.06	32.46	34.32	22.77	25.05	69.57	799.80	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	86.08	79.35	177.30	562.52	171.03	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.02	0.02	0.02	0.01	0.00	0.00	0.04
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.58	-0.63	-0.60	-0.61	-0.58	-0.60	-0.61	-0.58	-0.58	-0.59	-0.62
Leverage Ratio	1.50	1.40	1.32	1.28	1.25	1.23	1.25	1.20	1.18	1.22	1.21
Compound Leverage Factor	1.50	1.40	1.32	1.28	1.25	1.23	1.25	1.20	1.18	1.22	1.21
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	2.11%	2.11%	2.05%	1.47%	0.00%	0.00%	4.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	2.11%	2.11%	2.05%	1.47%	0.00%	0.00%	4.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	97.89%	97.89%	97.95%	98.53%	100.00%	100.00%	96.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	1.43	-0.42	-0.22	-0.11	0.00	0.00	-0.17
Net Debt to EBITDA	0.00	0.00	0.00	0.00	-37.80	12.04	6.66	4.52	0.00	0.00	2.40
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.20	-0.36	-0.24	-0.13	0.00	0.00	-0.24
Net Debt to NOPAT	0.00	0.00	0.00	0.00	-5.17	10.36	7.23	5.17	0.00	0.00	3.37
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	13.65	15.74	16.70	23.72	20.56	12.96	10.43	17.89	20.29	15.21	9.95
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.59	1.79	2.14	2.68	2.80	3.00	3.03	3.53	4.01	4.52	3.49
Quick Ratio	1.15	1.36	1.66	2.09	2.18	2.50	2.57	2.90	3.28	3.75	2.97
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-31	-24	8.63	7.96	-11	1.43	-3.39	-1.12	1.40	-10	-14
Operating Cash Flow to CapEx	184.78%	321.31%	1,449.87%	889.38%	185.11%	196.31%	425.52%	245.13%	377.81%	-257.14%	305.20%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	2.66	2.57	2.44	2.45	2.33	2.16	1.99	1.85	1.63	1.34	1.11
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	7.73	6.98	6.59	6.13	6.68	7.13	6.74	6.83	7.86	6.73	6.38
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	5.36	4.52	3.99	3.99	4.14	4.16	3.98	4.29	4.19	4.55	4.32
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	47.19	52.27	55.37	59.54	54.63	51.16	54.18	53.43	46.47	54.23	57.21
Days Payable Outstanding (DPO)	68.09	80.76	91.46	91.57	88.15	87.66	91.61	84.99	87.04	80.30	84.53
Cash Conversion Cycle (CCC)	-20.90	-28.49	-36.09	-32.03	-33.53	-36.50	-37.43	-31.56	-40.57	-26.07	-27.33
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	227	176	186	135	148	130	123	132	128	132	126
Invested Capital Turnover	9.52	9.62	8.04	8.01	6.94	6.64	6.38	5.29	4.63	4.02	3.53
Increase / (Decrease) in Invested Capital	78	46	63	2.97	20	-1.66	-2.60	-5.35	-9.28	1.94	-0.41
Enterprise Value (EV)	6,242	4,983	3,745	4,109	3,083	1,673	1,122	1,779	1,884	1,152	970
Market Capitalization	6,565	5,283	3,999	4,337	3,280	1,887	1,327	1,968	2,068	1,332	1,156
Book Value per Share	$2.47	$2.18	$2.03	$1.69	$1.61	$1.62	$1.56	$1.53	$1.50	$1.50	$1.50
Tangible Book Value per Share	$1.75	$1.47	$1.30	$1.09	$1.01	$1.01	$0.94	$0.90	$0.87	$0.86	$0.86
Total Capital	549	477	440	362	352	351	335	325	313	312	324
Total Debt	0.00	0.00	0.00	0.00	7.41	7.41	6.86	4.78	0.00	0.00	13
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-323	-300	-254	-227	-196	-214	-206	-188	-184	-180	-185
Capital Expenditures (CapEx)	59	27	5.88	6.03	14	11	5.92	6.86	2.51	2.61	1.96
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-156	-126	-80	-45	-28	-37	-38	-20	-15	-11	-19
Debt-free Net Working Capital (DFNWC)	167	174	174	182	176	184	175	173	169	169	180
Net Working Capital (NWC)	167	174	174	182	168	177	168	168	169	169	167
Net Nonoperating Expense (NNE)	-2.13	-4.31	-3.91	-2.37	-2.24	-1.47	1.58	0.69	2.18	2.78	4.85
Net Nonoperating Obligations (NNO)	-323	-300	-254	-227	-196	-214	-206	-188	-184	-180	-185
Total Depreciation and Amortization (D&A)	7.58	5.15	3.22	2.44	1.92	1.01	0.85	0.90	1.08	1.17	2.03
Debt-free, Cash-free Net Working Capital to Revenue	-8.75%	-8.52%	-6.47%	-4.22%	-2.89%	-4.24%	-4.79%	-2.85%	-2.46%	-2.08%	-4.23%
Debt-free Net Working Capital to Revenue	9.34%	11.82%	13.99%	17.08%	18.33%	21.10%	22.02%	24.32%	27.46%	32.01%	40.42%
Net Working Capital to Revenue	9.34%	11.82%	13.99%	17.08%	17.55%	20.25%	21.16%	23.65%	27.46%	32.01%	37.50%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.22	$0.12	$0.35	$0.06	$0.05	$0.01	($0.04)	($0.03)	($0.05)	($0.05)	($0.09)
Adjusted Weighted Average Basic Shares Outstanding	221.99M	215.94M	216.62M	214.62M	213.45M	209.34M	210.13M	208.42M	207.14M	204.52M	205.23M
Adjusted Diluted Earnings per Share	$0.20	$0.10	$0.32	$0.06	$0.05	$0.01	($0.04)	($0.03)	($0.05)	($0.05)	($0.09)
Adjusted Weighted Average Diluted Shares Outstanding	246.61M	236.81M	235.07M	234.79M	229.36M	209.34M	210.13M	208.42M	207.14M	204.52M	205.23M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	223.83M	222.17M	218.48M	217.08M	214.79M	214.25M	211.99M	211.02M	209.32M	208.46M	207.74M
Normalized Net Operating Profit after Tax (NOPAT)	47	13	16	11	8.88	-0.23	-5.99	-6.47	-7.88	-8.12	-14
Normalized NOPAT Margin	8.08%	2.71%	3.90%	3.46%	3.19%	-0.09%	-2.64%	-3.11%	-4.13%	-4.86%	-9.66%
Pre Tax Income Margin	10.32%	4.63%	5.88%	4.25%	4.46%	0.89%	-3.05%	-3.45%	-5.07%	-6.60%	-13.02%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	33.44%	65.88%	79.04%	276.17%	-1,278.73%	-8.49%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Hims & Hers Health's Financials

When does Hims & Hers Health's fiscal year end?

According to the most recent income statement we have on file, Hims & Hers Health's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Hims & Hers Health's net income changed over the last 5 years?

Hims & Hers Health's net income appears to be on a downward trend, with a most recent value of $126.04 million in 2024, falling from -$72.06 million in 2019. The previous period was -$23.55 million in 2023. See Hims & Hers Health's forecast for analyst expectations on what’s next for the company.

What is Hims & Hers Health's operating income?

Hims & Hers Health's total operating income in 2024 was $61.90 million, based on the following breakdown:

Total Gross Profit: $1.17 billion
Total Operating Expenses: $1.11 billion

How has Hims & Hers Health revenue changed over the last 5 years?

Over the last 5 years, Hims & Hers Health's total revenue changed from $82.56 million in 2019 to $1.48 billion in 2024, a change of 1,688.5%.

How much debt does Hims & Hers Health have?

Hims & Hers Health's total liabilities were at $230.82 million at the end of 2024, a 137.6% increase from 2023, and a 2,724.2% increase since 2019.

How much cash does Hims & Hers Health have?

In the past 5 years, Hims & Hers Health's cash and equivalents has ranged from $1.51 million in 2019 to $220.58 million in 2024, and is currently $220.58 million as of their latest financial filing in 2024.

How has Hims & Hers Health's book value per share changed over the last 5 years?

Over the last 5 years, Hims & Hers Health's book value per share changed from 0.20 in 2019 to 2.18 in 2024, a change of 997.6%.

Related Companies

This page (NYSE:HIMS) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hims & Hers Health (HIMS) Financials

Frequently Asked Questions About Hims & Hers Health's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hims & Hers Health (HIMS) Financials

Annual Income Statements for Hims & Hers Health

Quarterly Income Statements for Hims & Hers Health

Annual Cash Flow Statements for Hims & Hers Health

Quarterly Cash Flow Statements for Hims & Hers Health

Annual Balance Sheets for Hims & Hers Health

Quarterly Balance Sheets for Hims & Hers Health

Annual Metrics And Ratios for Hims & Hers Health

Quarterly Metrics And Ratios for Hims & Hers Health

Frequently Asked Questions About Hims & Hers Health's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools